Celestine Schnugg

Monod Bio is a pioneer company in the design of de novo protein biosensors. Our innovative biosensor platform technology takes advantage of the most recent advances in computational protein engineering to create highly modular biosensing nanoswitches that enable rapid, sensitive, and inexpensive analytical assays. Our visionary founding team and state-of-the-art technology position Monod Bio at the forefront of biosensor innovation, and we welcome exceptional individuals to join us in this journey.

Impulse Space, the in-space mobility company, is accelerating our future beyond Earth beginning with a fleet of cost-effective, high-performance space vehicles. Founded by Tom Mueller and led by a team of industry pioneers, Impulse Space is transforming in-space mobility by reliably and rapidly getting customers where they want to go.

We develop AI and wet-lab technologies that enable the rational design of developable, selective, and functional drugs against previously undruggable targets. To maximize the patient impact of our platform, we collaborate with leading pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb and Takeda, to expand their pipelines with high-quality drug candidates. If successful we could double the number of disease-relevant drug targets the industry advances for drug development. Since launching in 2021 we have raised $37 million with the backing of leading investors, including Radical Ventures, Khosla Ventures and Zetta Venture Partners. Our technical team is based in Cambridge, Massachusetts and continues to recruit top machine learning and synthetic biology talent. For more information check out the Careers section of our website at www.nabla.bio.

Merlin is the aviation technology company propelling the future of fully autonomous flight.

Endpoint Health is a Precision-First therapeutics company dedicated to addressing unmet needs in immune-mediated chronic and acute diseases. We leverage our proprietary artificial intelligence (AI) platform and combine companion diagnostics with therapeutics to develop precision therapies. Our vision is a world in which all patients get the best treatment possible for their unique biology and disease.

A-Alpha Bio is a biotechnology company using synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions. We pursue our mission of improving human health through an internal therapeutics pipeline and by partnering with industry-leading pharmaceutical and technology companies. Current approaches for measuring protein-protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. Our proprietary experimental platform, AlphaSeq, generates high-resolution data to discover rare and effective antibodies, identify degradable neo-substrates for molecular glues, and generate massive protein-protein interaction datasets to map the protein binding landscape. Our AlphaBind platform then leverages these data to train predictive machine learning models to further accelerate the discovery and optimization of high-impact therapeutics. A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology and is based in Seattle, Washington.

Fauna Bio is inspired by the untapped potential of non-model organism biology. We leverage insights from extraordinary mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans.

Herophilus is a San Francisco based neurotherapeutics development company that employs AI-driven phenotypic screening to discover and develop novel drugs for complex brain diseases, disorders for which traditional discovery techniques have proved least successful. Herophilus industrializes the recent revolution in complex in vitro experimental science, leveraging robotic automation and machine learning, to characterize the etiology and expression of disease at molecular, cellular, and tissue levels. These "deep phenotypes"​ are exploited to identify novel therapeutic targets and drug treatments.

Swarm enables global connectivity with the world's most affordable satellite network.

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

We are a human-centered robotics company. Our mission is to make technical advances towards robots and humans working together side by side, with an emphasis on human-centric design. Diligent Robotics is developing a suite of artificial intelligence that enables robots to collaborate with and adapt to humans in everyday environments. Our service robots are designed to participate and work together with teams of humans. Our first product is a hospital service robot that can assist clinical staff with logistical tasks, allowing them to spend more of their time on direct patient care, improving patient satisfaction, quality of service, and safety.

Mobile, containerized launch on demand and flight-proven satellite propulsion for responsive access to space.

Planet is the leading provider of global, daily satellite imagery and insights. Planet is driven by a mission to image all of Earth’s landmass every day, and make global change visible, accessible, and actionable. Founded in 2010 by three NASA scientists, Planet designs, builds, and operates the largest fleet of imaging satellites, as well as online software, tools and analytics needed to deliver data to users. Decision makers in business, government, and within organizations use Planets data and machine learning-powered analytics to develop new technologies, drive revenue, power research, and make informed, timely decisions to solve our worlds toughest challenges. Visit us at https://www.planet.com/

The Stanford Graduate School of Business empowers individuals to envision what is possible and make it happen through principled leadership and creative problem solving. The school has built a global reputation based on its management and leadership programs, including the two-year MBA; the one-year MSx Program; the PhD Program; Stanford Ignite, a part-time program in innovation and entrepreneurship; and Executive Education. Each program creates an experience that transforms people and prepares them to change lives, change organizations, and change the world. Programs engage the highest quality students with world-class faculty from across Stanford University’s seven schools, as well as alumni, Silicon Valley professionals, global executives, and the broader world community. The state-of-the-art Knight Management Center offers flexible classroom spaces for hands-on experiential learning, small-group leadership labs, and team-based learning. It also serves as a convening space for major forums and discussions.

Monod Bio is a pioneer company in the design of de novo protein biosensors. Our innovative biosensor platform technology takes advantage of the most recent advances in computational protein engineering to create highly modular biosensing nanoswitches that enable rapid, sensitive, and inexpensive analytical assays. Our visionary founding team and state-of-the-art technology position Monod Bio at the forefront of biosensor innovation, and we welcome exceptional individuals to join us in this journey.

Impulse Space, the in-space mobility company, is accelerating our future beyond Earth beginning with a fleet of cost-effective, high-performance space vehicles. Founded by Tom Mueller and led by a team of industry pioneers, Impulse Space is transforming in-space mobility by reliably and rapidly getting customers where they want to go.

SpaceX designs, manufactures and launches the world’s most advanced rockets and spacecraft. The company was founded in 2002 by Elon Musk to revolutionize space transportation, with the ultimate goal of making life multiplanetary. SpaceX has gained worldwide attention for a series of historic milestones. It is the only private company ever to return a spacecraft from low-Earth orbit, which it first accomplished in December 2010. The company made history again in May 2012 when its Dragon spacecraft attached to the International Space Station, exchanged cargo payloads, and returned safely to Earth — a technically challenging feat previously accomplished only by governments. Since then Dragon has delivered cargo to and from the space station multiple times, providing regular cargo resupply missions for NASA. For more information, visit www.spacex.com.

We develop AI and wet-lab technologies that enable the rational design of developable, selective, and functional drugs against previously undruggable targets. To maximize the patient impact of our platform, we collaborate with leading pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb and Takeda, to expand their pipelines with high-quality drug candidates. If successful we could double the number of disease-relevant drug targets the industry advances for drug development. Since launching in 2021 we have raised $37 million with the backing of leading investors, including Radical Ventures, Khosla Ventures and Zetta Venture Partners. Our technical team is based in Cambridge, Massachusetts and continues to recruit top machine learning and synthetic biology talent. For more information check out the Careers section of our website at www.nabla.bio.